nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—ABCB1—melanoma	0.155	1	CbGaD
Risperidone—CYP3A4—Temozolomide—melanoma	0.0499	0.189	CbGbCtD
Risperidone—CYP2D6—Vemurafenib—melanoma	0.043	0.163	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0321	0.122	CbGbCtD
Risperidone—CYP3A7—Docetaxel—melanoma	0.0321	0.122	CbGbCtD
Risperidone—ABCB1—Dactinomycin—melanoma	0.0303	0.115	CbGbCtD
Risperidone—CYP3A4—Vemurafenib—melanoma	0.0273	0.104	CbGbCtD
Risperidone—CYP3A5—Docetaxel—melanoma	0.0241	0.0912	CbGbCtD
Risperidone—HTR1D—meninx—melanoma	0.0176	0.287	CbGeAlD
Risperidone—ABCB1—Docetaxel—melanoma	0.0157	0.0594	CbGbCtD
Risperidone—CYP3A4—Docetaxel—melanoma	0.00938	0.0356	CbGbCtD
Risperidone—H1F0—hair follicle—melanoma	0.00274	0.0448	CbGeAlD
Risperidone—HTR2A—hindlimb—melanoma	0.00207	0.0339	CbGeAlD
Risperidone—HTR1B—blood vessel—melanoma	0.00206	0.0336	CbGeAlD
Risperidone—HTR1D—blood vessel—melanoma	0.00199	0.0325	CbGeAlD
Risperidone—H1F0—neck—melanoma	0.00184	0.0301	CbGeAlD
Risperidone—HTR2A—appendage—melanoma	0.00178	0.029	CbGeAlD
Risperidone—HTR7—endothelium—melanoma	0.00172	0.0281	CbGeAlD
Risperidone—HTR7—blood vessel—melanoma	0.00159	0.0259	CbGeAlD
Risperidone—H1F0—retina—melanoma	0.00136	0.0222	CbGeAlD
Risperidone—H1F0—skin of body—melanoma	0.00119	0.0195	CbGeAlD
Risperidone—HTR7—neck—melanoma	0.00113	0.0185	CbGeAlD
Risperidone—H1F0—mammalian vulva—melanoma	0.00109	0.0177	CbGeAlD
Risperidone—HTR2A—endothelium—melanoma	0.00107	0.0175	CbGeAlD
Risperidone—DRD3—head—melanoma	0.00107	0.0175	CbGeAlD
Risperidone—HTR1D—eye—melanoma	0.00106	0.0173	CbGeAlD
Risperidone—HTR2A—blood vessel—melanoma	0.000989	0.0162	CbGeAlD
Risperidone—HTR2B—skin of body—melanoma	0.000858	0.014	CbGeAlD
Risperidone—ADRA1B—head—melanoma	0.000823	0.0134	CbGeAlD
Risperidone—DRD2—eye—melanoma	0.000798	0.013	CbGeAlD
Risperidone—DRD2—retina—melanoma	0.000791	0.0129	CbGeAlD
Risperidone—H1F0—head—melanoma	0.000777	0.0127	CbGeAlD
Risperidone—DRD1—head—melanoma	0.000767	0.0125	CbGeAlD
Risperidone—HTR2A—neck—melanoma	0.000708	0.0116	CbGeAlD
Risperidone—ABCB1—blood vessel—melanoma	0.000648	0.0106	CbGeAlD
Risperidone—HRH1—eye—melanoma	0.00063	0.0103	CbGeAlD
Risperidone—HTR1B—head—melanoma	0.000621	0.0102	CbGeAlD
Risperidone—ADRA2C—mammalian vulva—melanoma	0.000616	0.0101	CbGeAlD
Risperidone—HTR1D—head—melanoma	0.000602	0.00983	CbGeAlD
Risperidone—HTR2C—head—melanoma	0.000596	0.00974	CbGeAlD
Risperidone—HTR2B—head—melanoma	0.00056	0.00915	CbGeAlD
Risperidone—H1F0—lymph node—melanoma	0.000544	0.00889	CbGeAlD
Risperidone—HTR2A—eye—melanoma	0.000526	0.0086	CbGeAlD
Risperidone—HTR2A—retina—melanoma	0.000522	0.00853	CbGeAlD
Risperidone—HTR1A—head—melanoma	0.000501	0.00819	CbGeAlD
Risperidone—HRH1—mammalian vulva—melanoma	0.0005	0.00817	CbGeAlD
Risperidone—ADRA2A—mammalian vulva—melanoma	0.000491	0.00803	CbGeAlD
Risperidone—HTR7—head—melanoma	0.000479	0.00783	CbGeAlD
Risperidone—ADRA1A—head—melanoma	0.000462	0.00755	CbGeAlD
Risperidone—DRD2—head—melanoma	0.000453	0.0074	CbGeAlD
Risperidone—KCNH2—head—melanoma	0.000446	0.0073	CbGeAlD
Risperidone—ADRA2C—head—melanoma	0.00044	0.0072	CbGeAlD
Risperidone—HTR2B—lymph node—melanoma	0.000392	0.0064	CbGeAlD
Risperidone—HRH1—head—melanoma	0.000358	0.00585	CbGeAlD
Risperidone—ADRA2A—head—melanoma	0.000351	0.00574	CbGeAlD
Risperidone—ABCB1—retina—melanoma	0.000342	0.00559	CbGeAlD
Risperidone—KCNH2—lymph node—melanoma	0.000313	0.00511	CbGeAlD
Risperidone—ADRA2C—lymph node—melanoma	0.000308	0.00504	CbGeAlD
Risperidone—HTR2A—head—melanoma	0.000299	0.00488	CbGeAlD
Risperidone—ABCB1—mammalian vulva—melanoma	0.000274	0.00447	CbGeAlD
Risperidone—Abdominal pain upper—Docetaxel—melanoma	0.000273	0.000918	CcSEcCtD
Risperidone—Orthostatic hypotension—Docetaxel—melanoma	0.000273	0.000918	CcSEcCtD
Risperidone—Rash—Vemurafenib—melanoma	0.000273	0.000916	CcSEcCtD
Risperidone—Mental disorder—Temozolomide—melanoma	0.000273	0.000916	CcSEcCtD
Risperidone—Dermatitis—Vemurafenib—melanoma	0.000273	0.000915	CcSEcCtD
Risperidone—CYP2D6—head—melanoma	0.000272	0.00445	CbGeAlD
Risperidone—Back pain—Carmustine—melanoma	0.000271	0.000911	CcSEcCtD
Risperidone—Headache—Vemurafenib—melanoma	0.000271	0.00091	CcSEcCtD
Risperidone—Malnutrition—Temozolomide—melanoma	0.000271	0.00091	CcSEcCtD
Risperidone—Erythema—Temozolomide—melanoma	0.000271	0.00091	CcSEcCtD
Risperidone—Breast disorder—Docetaxel—melanoma	0.00027	0.000908	CcSEcCtD
Risperidone—Discomfort—Bleomycin—melanoma	0.00027	0.000907	CcSEcCtD
Risperidone—Malaise—Dactinomycin—melanoma	0.00027	0.000907	CcSEcCtD
Risperidone—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00027	0.000905	CcSEcCtD
Risperidone—Leukopenia—Dactinomycin—melanoma	0.000268	0.0009	CcSEcCtD
Risperidone—Nasopharyngitis—Docetaxel—melanoma	0.000268	0.000898	CcSEcCtD
Risperidone—Dysgeusia—Temozolomide—melanoma	0.000265	0.000891	CcSEcCtD
Risperidone—Confusional state—Bleomycin—melanoma	0.000264	0.000888	CcSEcCtD
Risperidone—Vision blurred—Carmustine—melanoma	0.000264	0.000887	CcSEcCtD
Risperidone—Alanine aminotransferase increased—Docetaxel—melanoma	0.000264	0.000886	CcSEcCtD
Risperidone—Tremor—Carmustine—melanoma	0.000263	0.000882	CcSEcCtD
Risperidone—Oedema—Bleomycin—melanoma	0.000262	0.00088	CcSEcCtD
Risperidone—Anaphylactic shock—Bleomycin—melanoma	0.000262	0.00088	CcSEcCtD
Risperidone—Back pain—Temozolomide—melanoma	0.000262	0.00088	CcSEcCtD
Risperidone—Infection—Bleomycin—melanoma	0.000261	0.000875	CcSEcCtD
Risperidone—Anaemia—Carmustine—melanoma	0.000259	0.00087	CcSEcCtD
Risperidone—Dysphagia—Docetaxel—melanoma	0.000259	0.000868	CcSEcCtD
Risperidone—Agitation—Carmustine—melanoma	0.000258	0.000865	CcSEcCtD
Risperidone—Nausea—Vemurafenib—melanoma	0.000257	0.000863	CcSEcCtD
Risperidone—Thrombocytopenia—Bleomycin—melanoma	0.000257	0.000862	CcSEcCtD
Risperidone—Vision blurred—Temozolomide—melanoma	0.000255	0.000857	CcSEcCtD
Risperidone—Myalgia—Dactinomycin—melanoma	0.000255	0.000856	CcSEcCtD
Risperidone—Bronchospasm—Docetaxel—melanoma	0.000254	0.000854	CcSEcCtD
Risperidone—Tremor—Temozolomide—melanoma	0.000254	0.000852	CcSEcCtD
Risperidone—Discomfort—Dactinomycin—melanoma	0.000252	0.000846	CcSEcCtD
Risperidone—Angina pectoris—Docetaxel—melanoma	0.000252	0.000846	CcSEcCtD
Risperidone—Ill-defined disorder—Temozolomide—melanoma	0.000251	0.000844	CcSEcCtD
Risperidone—Leukopenia—Carmustine—melanoma	0.000251	0.000843	CcSEcCtD
Risperidone—HRH1—lymph node—melanoma	0.000251	0.00409	CbGeAlD
Risperidone—Anaemia—Temozolomide—melanoma	0.00025	0.000841	CcSEcCtD
Risperidone—Anorexia—Bleomycin—melanoma	0.00025	0.000839	CcSEcCtD
Risperidone—Agitation—Temozolomide—melanoma	0.000249	0.000836	CcSEcCtD
Risperidone—Angioedema—Temozolomide—melanoma	0.000248	0.000831	CcSEcCtD
Risperidone—ADRA2A—lymph node—melanoma	0.000246	0.00402	CbGeAlD
Risperidone—Hypotension—Bleomycin—melanoma	0.000245	0.000823	CcSEcCtD
Risperidone—Oedema—Dactinomycin—melanoma	0.000245	0.000821	CcSEcCtD
Risperidone—Malaise—Temozolomide—melanoma	0.000244	0.00082	CcSEcCtD
Risperidone—Vertigo—Temozolomide—melanoma	0.000243	0.000817	CcSEcCtD
Risperidone—Convulsion—Carmustine—melanoma	0.000243	0.000816	CcSEcCtD
Risperidone—Infection—Dactinomycin—melanoma	0.000243	0.000816	CcSEcCtD
Risperidone—Leukopenia—Temozolomide—melanoma	0.000243	0.000814	CcSEcCtD
Risperidone—Hypertension—Carmustine—melanoma	0.000242	0.000813	CcSEcCtD
Risperidone—Neutropenia—Docetaxel—melanoma	0.000242	0.000812	CcSEcCtD
Risperidone—Palpitations—Temozolomide—melanoma	0.00024	0.000804	CcSEcCtD
Risperidone—Thrombocytopenia—Dactinomycin—melanoma	0.000239	0.000804	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Bleomycin—melanoma	0.000239	0.000802	CcSEcCtD
Risperidone—Chest pain—Carmustine—melanoma	0.000239	0.000802	CcSEcCtD
Risperidone—Myalgia—Carmustine—melanoma	0.000239	0.000802	CcSEcCtD
Risperidone—Anxiety—Carmustine—melanoma	0.000238	0.000799	CcSEcCtD
Risperidone—Cough—Temozolomide—melanoma	0.000237	0.000794	CcSEcCtD
Risperidone—Paraesthesia—Bleomycin—melanoma	0.000235	0.00079	CcSEcCtD
Risperidone—Weight increased—Docetaxel—melanoma	0.000235	0.00079	CcSEcCtD
Risperidone—Convulsion—Temozolomide—melanoma	0.000235	0.000788	CcSEcCtD
Risperidone—Weight decreased—Docetaxel—melanoma	0.000234	0.000786	CcSEcCtD
Risperidone—Hypertension—Temozolomide—melanoma	0.000234	0.000786	CcSEcCtD
Risperidone—Dyspnoea—Bleomycin—melanoma	0.000234	0.000785	CcSEcCtD
Risperidone—Anorexia—Dactinomycin—melanoma	0.000233	0.000783	CcSEcCtD
Risperidone—Pneumonia—Docetaxel—melanoma	0.000232	0.000779	CcSEcCtD
Risperidone—Confusional state—Carmustine—melanoma	0.000231	0.000775	CcSEcCtD
Risperidone—Arthralgia—Temozolomide—melanoma	0.000231	0.000775	CcSEcCtD
Risperidone—Myalgia—Temozolomide—melanoma	0.000231	0.000775	CcSEcCtD
Risperidone—Infestation NOS—Docetaxel—melanoma	0.000231	0.000774	CcSEcCtD
Risperidone—Infestation—Docetaxel—melanoma	0.000231	0.000774	CcSEcCtD
Risperidone—Anxiety—Temozolomide—melanoma	0.00023	0.000772	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000229	0.000769	CcSEcCtD
Risperidone—Oedema—Carmustine—melanoma	0.000229	0.000768	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000229	0.000768	CcSEcCtD
Risperidone—Discomfort—Temozolomide—melanoma	0.000228	0.000765	CcSEcCtD
Risperidone—Decreased appetite—Bleomycin—melanoma	0.000228	0.000765	CcSEcCtD
Risperidone—Infection—Carmustine—melanoma	0.000227	0.000763	CcSEcCtD
Risperidone—Acute coronary syndrome—Docetaxel—melanoma	0.000227	0.000763	CcSEcCtD
Risperidone—Renal failure—Docetaxel—melanoma	0.000227	0.000761	CcSEcCtD
Risperidone—Neuropathy peripheral—Docetaxel—melanoma	0.000226	0.000759	CcSEcCtD
Risperidone—Myocardial infarction—Docetaxel—melanoma	0.000226	0.000759	CcSEcCtD
Risperidone—Dry mouth—Temozolomide—melanoma	0.000226	0.000758	CcSEcCtD
Risperidone—Jaundice—Docetaxel—melanoma	0.000225	0.000755	CcSEcCtD
Risperidone—Stomatitis—Docetaxel—melanoma	0.000225	0.000755	CcSEcCtD
Risperidone—Pain—Bleomycin—melanoma	0.000224	0.000753	CcSEcCtD
Risperidone—Conjunctivitis—Docetaxel—melanoma	0.000224	0.000753	CcSEcCtD
Risperidone—Thrombocytopenia—Carmustine—melanoma	0.000224	0.000752	CcSEcCtD
Risperidone—Tachycardia—Carmustine—melanoma	0.000223	0.00075	CcSEcCtD
Risperidone—Confusional state—Temozolomide—melanoma	0.000223	0.000749	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000223	0.000748	CcSEcCtD
Risperidone—Oedema—Temozolomide—melanoma	0.000221	0.000743	CcSEcCtD
Risperidone—Anaphylactic shock—Temozolomide—melanoma	0.000221	0.000743	CcSEcCtD
Risperidone—Infection—Temozolomide—melanoma	0.00022	0.000738	CcSEcCtD
Risperidone—Anorexia—Carmustine—melanoma	0.000218	0.000732	CcSEcCtD
Risperidone—Hepatobiliary disease—Docetaxel—melanoma	0.000218	0.000732	CcSEcCtD
Risperidone—Epistaxis—Docetaxel—melanoma	0.000218	0.00073	CcSEcCtD
Risperidone—Nervous system disorder—Temozolomide—melanoma	0.000217	0.000728	CcSEcCtD
Risperidone—Thrombocytopenia—Temozolomide—melanoma	0.000217	0.000727	CcSEcCtD
Risperidone—Feeling abnormal—Bleomycin—melanoma	0.000216	0.000725	CcSEcCtD
Risperidone—Agranulocytosis—Docetaxel—melanoma	0.000215	0.000723	CcSEcCtD
Risperidone—Skin disorder—Temozolomide—melanoma	0.000215	0.000721	CcSEcCtD
Risperidone—Hypotension—Carmustine—melanoma	0.000214	0.000718	CcSEcCtD
Risperidone—Hyperhidrosis—Temozolomide—melanoma	0.000214	0.000718	CcSEcCtD
Risperidone—Decreased appetite—Dactinomycin—melanoma	0.000213	0.000714	CcSEcCtD
Risperidone—Fatigue—Dactinomycin—melanoma	0.000211	0.000708	CcSEcCtD
Risperidone—Anorexia—Temozolomide—melanoma	0.000211	0.000708	CcSEcCtD
Risperidone—Pain—Dactinomycin—melanoma	0.000209	0.000702	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Carmustine—melanoma	0.000209	0.0007	CcSEcCtD
Risperidone—Urticaria—Bleomycin—melanoma	0.000208	0.000699	CcSEcCtD
Risperidone—Haemoglobin—Docetaxel—melanoma	0.000208	0.000699	CcSEcCtD
Risperidone—Rhinitis—Docetaxel—melanoma	0.000208	0.000697	CcSEcCtD
Risperidone—Body temperature increased—Bleomycin—melanoma	0.000207	0.000696	CcSEcCtD
Risperidone—Hepatitis—Docetaxel—melanoma	0.000207	0.000695	CcSEcCtD
Risperidone—Haemorrhage—Docetaxel—melanoma	0.000207	0.000695	CcSEcCtD
Risperidone—Insomnia—Carmustine—melanoma	0.000207	0.000695	CcSEcCtD
Risperidone—Hypoaesthesia—Docetaxel—melanoma	0.000206	0.000692	CcSEcCtD
Risperidone—Paraesthesia—Carmustine—melanoma	0.000206	0.00069	CcSEcCtD
Risperidone—Pharyngitis—Docetaxel—melanoma	0.000205	0.00069	CcSEcCtD
Risperidone—Urinary tract disorder—Docetaxel—melanoma	0.000204	0.000686	CcSEcCtD
Risperidone—Dyspnoea—Carmustine—melanoma	0.000204	0.000685	CcSEcCtD
Risperidone—Oedema peripheral—Docetaxel—melanoma	0.000204	0.000685	CcSEcCtD
Risperidone—Somnolence—Carmustine—melanoma	0.000203	0.000683	CcSEcCtD
Risperidone—Connective tissue disorder—Docetaxel—melanoma	0.000203	0.000683	CcSEcCtD
Risperidone—Urethral disorder—Docetaxel—melanoma	0.000203	0.000681	CcSEcCtD
Risperidone—Feeling abnormal—Dactinomycin—melanoma	0.000202	0.000677	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Temozolomide—melanoma	0.000202	0.000677	CcSEcCtD
Risperidone—Insomnia—Temozolomide—melanoma	0.0002	0.000672	CcSEcCtD
Risperidone—Gastrointestinal pain—Dactinomycin—melanoma	0.0002	0.000671	CcSEcCtD
Risperidone—Visual impairment—Docetaxel—melanoma	0.0002	0.00067	CcSEcCtD
Risperidone—Decreased appetite—Carmustine—melanoma	0.000199	0.000668	CcSEcCtD
Risperidone—Paraesthesia—Temozolomide—melanoma	0.000199	0.000667	CcSEcCtD
Risperidone—Gastrointestinal disorder—Carmustine—melanoma	0.000198	0.000663	CcSEcCtD
Risperidone—Dyspnoea—Temozolomide—melanoma	0.000197	0.000662	CcSEcCtD
Risperidone—Somnolence—Temozolomide—melanoma	0.000197	0.00066	CcSEcCtD
Risperidone—ABCB1—head—melanoma	0.000196	0.0032	CbGeAlD
Risperidone—Erythema multiforme—Docetaxel—melanoma	0.000196	0.000657	CcSEcCtD
Risperidone—Pain—Carmustine—melanoma	0.000196	0.000657	CcSEcCtD
Risperidone—Constipation—Carmustine—melanoma	0.000196	0.000657	CcSEcCtD
Risperidone—Dyspepsia—Temozolomide—melanoma	0.000195	0.000654	CcSEcCtD
Risperidone—Eye disorder—Docetaxel—melanoma	0.000193	0.00065	CcSEcCtD
Risperidone—Abdominal pain—Dactinomycin—melanoma	0.000193	0.000649	CcSEcCtD
Risperidone—Body temperature increased—Dactinomycin—melanoma	0.000193	0.000649	CcSEcCtD
Risperidone—Hypersensitivity—Bleomycin—melanoma	0.000193	0.000649	CcSEcCtD
Risperidone—Decreased appetite—Temozolomide—melanoma	0.000192	0.000646	CcSEcCtD
Risperidone—Flushing—Docetaxel—melanoma	0.000192	0.000645	CcSEcCtD
Risperidone—Cardiac disorder—Docetaxel—melanoma	0.000192	0.000645	CcSEcCtD
Risperidone—Gastrointestinal disorder—Temozolomide—melanoma	0.000191	0.000641	CcSEcCtD
Risperidone—Fatigue—Temozolomide—melanoma	0.000191	0.00064	CcSEcCtD
Risperidone—Pain—Temozolomide—melanoma	0.000189	0.000635	CcSEcCtD
Risperidone—Constipation—Temozolomide—melanoma	0.000189	0.000635	CcSEcCtD
Risperidone—Feeling abnormal—Carmustine—melanoma	0.000189	0.000633	CcSEcCtD
Risperidone—Asthenia—Bleomycin—melanoma	0.000188	0.000632	CcSEcCtD
Risperidone—Angiopathy—Docetaxel—melanoma	0.000188	0.000631	CcSEcCtD
Risperidone—Gastrointestinal pain—Carmustine—melanoma	0.000187	0.000628	CcSEcCtD
Risperidone—Immune system disorder—Docetaxel—melanoma	0.000187	0.000628	CcSEcCtD
Risperidone—Mediastinal disorder—Docetaxel—melanoma	0.000187	0.000626	CcSEcCtD
Risperidone—Chills—Docetaxel—melanoma	0.000186	0.000624	CcSEcCtD
Risperidone—Pruritus—Bleomycin—melanoma	0.000186	0.000623	CcSEcCtD
Risperidone—Arrhythmia—Docetaxel—melanoma	0.000185	0.000621	CcSEcCtD
Risperidone—Alopecia—Docetaxel—melanoma	0.000183	0.000614	CcSEcCtD
Risperidone—Feeling abnormal—Temozolomide—melanoma	0.000182	0.000612	CcSEcCtD
Risperidone—Mental disorder—Docetaxel—melanoma	0.000181	0.000609	CcSEcCtD
Risperidone—Abdominal pain—Carmustine—melanoma	0.000181	0.000607	CcSEcCtD
Risperidone—Body temperature increased—Carmustine—melanoma	0.000181	0.000607	CcSEcCtD
Risperidone—Gastrointestinal pain—Temozolomide—melanoma	0.000181	0.000607	CcSEcCtD
Risperidone—Malnutrition—Docetaxel—melanoma	0.00018	0.000605	CcSEcCtD
Risperidone—Erythema—Docetaxel—melanoma	0.00018	0.000605	CcSEcCtD
Risperidone—Hypersensitivity—Dactinomycin—melanoma	0.00018	0.000605	CcSEcCtD
Risperidone—Dysgeusia—Docetaxel—melanoma	0.000176	0.000593	CcSEcCtD
Risperidone—Urticaria—Temozolomide—melanoma	0.000176	0.00059	CcSEcCtD
Risperidone—Asthenia—Dactinomycin—melanoma	0.000175	0.000589	CcSEcCtD
Risperidone—Abdominal pain—Temozolomide—melanoma	0.000175	0.000587	CcSEcCtD
Risperidone—Body temperature increased—Temozolomide—melanoma	0.000175	0.000587	CcSEcCtD
Risperidone—Back pain—Docetaxel—melanoma	0.000174	0.000585	CcSEcCtD
Risperidone—Muscle spasms—Docetaxel—melanoma	0.000173	0.000582	CcSEcCtD
Risperidone—Hypersensitivity—Carmustine—melanoma	0.000169	0.000566	CcSEcCtD
Risperidone—Diarrhoea—Dactinomycin—melanoma	0.000167	0.000562	CcSEcCtD
Risperidone—Vomiting—Bleomycin—melanoma	0.000167	0.00056	CcSEcCtD
Risperidone—Anaemia—Docetaxel—melanoma	0.000167	0.000559	CcSEcCtD
Risperidone—Rash—Bleomycin—melanoma	0.000165	0.000555	CcSEcCtD
Risperidone—Dermatitis—Bleomycin—melanoma	0.000165	0.000555	CcSEcCtD
Risperidone—Asthenia—Carmustine—melanoma	0.000164	0.000551	CcSEcCtD
Risperidone—Hypersensitivity—Temozolomide—melanoma	0.000163	0.000547	CcSEcCtD
Risperidone—Syncope—Docetaxel—melanoma	0.000162	0.000543	CcSEcCtD
Risperidone—Leukopenia—Docetaxel—melanoma	0.000161	0.000542	CcSEcCtD
Risperidone—Palpitations—Docetaxel—melanoma	0.000159	0.000535	CcSEcCtD
Risperidone—Asthenia—Temozolomide—melanoma	0.000159	0.000533	CcSEcCtD
Risperidone—Loss of consciousness—Docetaxel—melanoma	0.000158	0.000532	CcSEcCtD
Risperidone—Cough—Docetaxel—melanoma	0.000157	0.000528	CcSEcCtD
Risperidone—Diarrhoea—Carmustine—melanoma	0.000157	0.000526	CcSEcCtD
Risperidone—Pruritus—Temozolomide—melanoma	0.000156	0.000525	CcSEcCtD
Risperidone—Convulsion—Docetaxel—melanoma	0.000156	0.000524	CcSEcCtD
Risperidone—Nausea—Bleomycin—melanoma	0.000156	0.000523	CcSEcCtD
Risperidone—Hypertension—Docetaxel—melanoma	0.000156	0.000522	CcSEcCtD
Risperidone—Vomiting—Dactinomycin—melanoma	0.000155	0.000522	CcSEcCtD
Risperidone—Rash—Dactinomycin—melanoma	0.000154	0.000518	CcSEcCtD
Risperidone—Arthralgia—Docetaxel—melanoma	0.000153	0.000515	CcSEcCtD
Risperidone—Chest pain—Docetaxel—melanoma	0.000153	0.000515	CcSEcCtD
Risperidone—Myalgia—Docetaxel—melanoma	0.000153	0.000515	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000152	0.000512	CcSEcCtD
Risperidone—Dizziness—Carmustine—melanoma	0.000151	0.000508	CcSEcCtD
Risperidone—Diarrhoea—Temozolomide—melanoma	0.000151	0.000508	CcSEcCtD
Risperidone—Dry mouth—Docetaxel—melanoma	0.00015	0.000504	CcSEcCtD
Risperidone—Confusional state—Docetaxel—melanoma	0.000148	0.000498	CcSEcCtD
Risperidone—Oedema—Docetaxel—melanoma	0.000147	0.000494	CcSEcCtD
Risperidone—Anaphylactic shock—Docetaxel—melanoma	0.000147	0.000494	CcSEcCtD
Risperidone—Dizziness—Temozolomide—melanoma	0.000146	0.000491	CcSEcCtD
Risperidone—Infection—Docetaxel—melanoma	0.000146	0.000491	CcSEcCtD
Risperidone—Vomiting—Carmustine—melanoma	0.000146	0.000489	CcSEcCtD
Risperidone—Nausea—Dactinomycin—melanoma	0.000145	0.000488	CcSEcCtD
Risperidone—Shock—Docetaxel—melanoma	0.000145	0.000486	CcSEcCtD
Risperidone—Rash—Carmustine—melanoma	0.000144	0.000484	CcSEcCtD
Risperidone—Nervous system disorder—Docetaxel—melanoma	0.000144	0.000484	CcSEcCtD
Risperidone—Dermatitis—Carmustine—melanoma	0.000144	0.000484	CcSEcCtD
Risperidone—Thrombocytopenia—Docetaxel—melanoma	0.000144	0.000483	CcSEcCtD
Risperidone—Tachycardia—Docetaxel—melanoma	0.000144	0.000482	CcSEcCtD
Risperidone—Headache—Carmustine—melanoma	0.000143	0.000481	CcSEcCtD
Risperidone—Skin disorder—Docetaxel—melanoma	0.000143	0.00048	CcSEcCtD
Risperidone—Vomiting—Temozolomide—melanoma	0.000141	0.000472	CcSEcCtD
Risperidone—Anorexia—Docetaxel—melanoma	0.00014	0.000471	CcSEcCtD
Risperidone—Rash—Temozolomide—melanoma	0.000139	0.000468	CcSEcCtD
Risperidone—Dermatitis—Temozolomide—melanoma	0.000139	0.000468	CcSEcCtD
Risperidone—Headache—Temozolomide—melanoma	0.000139	0.000465	CcSEcCtD
Risperidone—Hypotension—Docetaxel—melanoma	0.000137	0.000461	CcSEcCtD
Risperidone—ABCB1—lymph node—melanoma	0.000137	0.00224	CbGeAlD
Risperidone—Nausea—Carmustine—melanoma	0.000136	0.000456	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Docetaxel—melanoma	0.000134	0.00045	CcSEcCtD
Risperidone—Insomnia—Docetaxel—melanoma	0.000133	0.000447	CcSEcCtD
Risperidone—Paraesthesia—Docetaxel—melanoma	0.000132	0.000443	CcSEcCtD
Risperidone—Nausea—Temozolomide—melanoma	0.000131	0.000441	CcSEcCtD
Risperidone—Dyspnoea—Docetaxel—melanoma	0.000131	0.00044	CcSEcCtD
Risperidone—Somnolence—Docetaxel—melanoma	0.000131	0.000439	CcSEcCtD
Risperidone—Dyspepsia—Docetaxel—melanoma	0.000129	0.000435	CcSEcCtD
Risperidone—Decreased appetite—Docetaxel—melanoma	0.000128	0.000429	CcSEcCtD
Risperidone—Gastrointestinal disorder—Docetaxel—melanoma	0.000127	0.000426	CcSEcCtD
Risperidone—Fatigue—Docetaxel—melanoma	0.000127	0.000426	CcSEcCtD
Risperidone—Pain—Docetaxel—melanoma	0.000126	0.000422	CcSEcCtD
Risperidone—Constipation—Docetaxel—melanoma	0.000126	0.000422	CcSEcCtD
Risperidone—Feeling abnormal—Docetaxel—melanoma	0.000121	0.000407	CcSEcCtD
Risperidone—Gastrointestinal pain—Docetaxel—melanoma	0.00012	0.000404	CcSEcCtD
Risperidone—Abdominal pain—Docetaxel—melanoma	0.000116	0.00039	CcSEcCtD
Risperidone—Body temperature increased—Docetaxel—melanoma	0.000116	0.00039	CcSEcCtD
Risperidone—Hypersensitivity—Docetaxel—melanoma	0.000108	0.000364	CcSEcCtD
Risperidone—Asthenia—Docetaxel—melanoma	0.000106	0.000354	CcSEcCtD
Risperidone—Pruritus—Docetaxel—melanoma	0.000104	0.000349	CcSEcCtD
Risperidone—Diarrhoea—Docetaxel—melanoma	0.000101	0.000338	CcSEcCtD
Risperidone—Dizziness—Docetaxel—melanoma	9.73e-05	0.000327	CcSEcCtD
Risperidone—Vomiting—Docetaxel—melanoma	9.35e-05	0.000314	CcSEcCtD
Risperidone—Rash—Docetaxel—melanoma	9.27e-05	0.000311	CcSEcCtD
Risperidone—Dermatitis—Docetaxel—melanoma	9.27e-05	0.000311	CcSEcCtD
Risperidone—Headache—Docetaxel—melanoma	9.22e-05	0.000309	CcSEcCtD
Risperidone—Nausea—Docetaxel—melanoma	8.74e-05	0.000293	CcSEcCtD
Risperidone—HTR2A—Signaling Pathways—CASP3—melanoma	4.22e-06	1.9e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CDKN1B—melanoma	4.22e-06	1.9e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL2—melanoma	4.21e-06	1.89e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CASP3—melanoma	4.21e-06	1.89e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL2—melanoma	4.2e-06	1.89e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TP53—melanoma	4.2e-06	1.89e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—IL6—melanoma	4.19e-06	1.88e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—IL6—melanoma	4.18e-06	1.88e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—PIK3CA—melanoma	4.18e-06	1.88e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCND1—melanoma	4.17e-06	1.88e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CB—melanoma	4.17e-06	1.88e-05	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—AKT1—melanoma	4.17e-06	1.87e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—VEGFA—melanoma	4.14e-06	1.86e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CTNNB1—melanoma	4.13e-06	1.86e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CASP3—melanoma	4.13e-06	1.86e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL2—melanoma	4.12e-06	1.85e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—VEGFA—melanoma	4.12e-06	1.85e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TP53—melanoma	4.11e-06	1.85e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCND1—melanoma	4.11e-06	1.85e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—IL6—melanoma	4.1e-06	1.85e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—STAT3—melanoma	4.1e-06	1.85e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCND1—melanoma	4.1e-06	1.84e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—KRAS—melanoma	4.1e-06	1.84e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PPARG—melanoma	4.1e-06	1.84e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—NRAS—melanoma	4.09e-06	1.84e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—STAT3—melanoma	4.08e-06	1.84e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—NRAS—melanoma	4.07e-06	1.83e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CTNNB1—melanoma	4.07e-06	1.83e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK3—melanoma	4.06e-06	1.83e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CTNNB1—melanoma	4.06e-06	1.82e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MMP9—melanoma	4.05e-06	1.82e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TP53—melanoma	4.04e-06	1.82e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—KRAS—melanoma	4.04e-06	1.82e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—HRAS—melanoma	4.04e-06	1.82e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CDKN1A—melanoma	4.04e-06	1.82e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PTEN—melanoma	4.03e-06	1.81e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCND1—melanoma	4.02e-06	1.81e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—HRAS—melanoma	4.01e-06	1.81e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCL8—melanoma	4.01e-06	1.8e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—VEGFA—melanoma	4.01e-06	1.8e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NFKB1—melanoma	4.01e-06	1.8e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—PIK3CA—melanoma	3.99e-06	1.79e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MMP9—melanoma	3.99e-06	1.79e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—HRAS—melanoma	3.98e-06	1.79e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CTNNB1—melanoma	3.98e-06	1.79e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MMP9—melanoma	3.98e-06	1.79e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CDKN1A—melanoma	3.97e-06	1.79e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—STAT3—melanoma	3.97e-06	1.79e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CDKN1A—melanoma	3.96e-06	1.78e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PTEN—melanoma	3.96e-06	1.78e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—NRAS—melanoma	3.96e-06	1.78e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CD—melanoma	3.96e-06	1.78e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PTEN—melanoma	3.96e-06	1.78e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTEN—melanoma	3.95e-06	1.78e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MYC—melanoma	3.95e-06	1.78e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—VEGFA—melanoma	3.95e-06	1.77e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NFKB1—melanoma	3.94e-06	1.77e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NFKB1—melanoma	3.94e-06	1.77e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—HRAS—melanoma	3.93e-06	1.77e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—AKT1—melanoma	3.93e-06	1.77e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK3—melanoma	3.92e-06	1.76e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.92e-06	1.76e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—ALB—melanoma	3.91e-06	1.76e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—STAT3—melanoma	3.91e-06	1.76e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MMP9—melanoma	3.9e-06	1.76e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK3—melanoma	3.9e-06	1.75e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NRAS—melanoma	3.9e-06	1.75e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.89e-06	1.75e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PTEN—melanoma	3.88e-06	1.75e-05	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.87e-06	1.74e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—HRAS—melanoma	3.87e-06	1.74e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IL6—melanoma	3.87e-06	1.74e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—AKT1—melanoma	3.87e-06	1.74e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.86e-06	1.74e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EGFR—melanoma	3.86e-06	1.74e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.86e-06	1.74e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TP53—melanoma	3.86e-06	1.74e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—AKT1—melanoma	3.86e-06	1.74e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PIK3CA—melanoma	3.86e-06	1.73e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ABCB1—melanoma	3.85e-06	1.73e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IL6—melanoma	3.84e-06	1.73e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CASP3—melanoma	3.84e-06	1.73e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL2—melanoma	3.83e-06	1.72e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—IL6—melanoma	3.81e-06	1.71e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MYC—melanoma	3.81e-06	1.71e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK3—melanoma	3.79e-06	1.71e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MYC—melanoma	3.79e-06	1.71e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—AKT1—melanoma	3.79e-06	1.7e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—PIK3CA—melanoma	3.76e-06	1.69e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IL6—melanoma	3.76e-06	1.69e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PIK3CA—melanoma	3.75e-06	1.68e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCND1—melanoma	3.74e-06	1.68e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK3—melanoma	3.73e-06	1.68e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CD—melanoma	3.73e-06	1.68e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK1—melanoma	3.73e-06	1.68e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EGFR—melanoma	3.73e-06	1.68e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—PIK3CA—melanoma	3.71e-06	1.67e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK1—melanoma	3.71e-06	1.67e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EGFR—melanoma	3.71e-06	1.67e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IL6—melanoma	3.7e-06	1.66e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CTNNB1—melanoma	3.7e-06	1.66e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—HRAS—melanoma	3.69e-06	1.66e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MYC—melanoma	3.69e-06	1.66e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—ALB—melanoma	3.68e-06	1.66e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—KRAS—melanoma	3.65e-06	1.64e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TP53—melanoma	3.64e-06	1.64e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—VEGFA—melanoma	3.64e-06	1.64e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MYC—melanoma	3.63e-06	1.63e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MMP9—melanoma	3.63e-06	1.63e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CDKN1A—melanoma	3.61e-06	1.63e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK1—melanoma	3.61e-06	1.62e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EGFR—melanoma	3.61e-06	1.62e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PTEN—melanoma	3.61e-06	1.62e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—STAT3—melanoma	3.6e-06	1.62e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NRAS—melanoma	3.59e-06	1.62e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TP53—melanoma	3.59e-06	1.62e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NFKB1—melanoma	3.59e-06	1.61e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—VEGFA—melanoma	3.58e-06	1.61e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—VEGFA—melanoma	3.57e-06	1.61e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—AKT1—melanoma	3.57e-06	1.6e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK1—melanoma	3.55e-06	1.6e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EGFR—melanoma	3.55e-06	1.6e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—STAT3—melanoma	3.54e-06	1.59e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—AKT1—melanoma	3.54e-06	1.59e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PRKCA—melanoma	3.54e-06	1.59e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—STAT3—melanoma	3.54e-06	1.59e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NRAS—melanoma	3.54e-06	1.59e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IL6—melanoma	3.53e-06	1.59e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NRAS—melanoma	3.53e-06	1.59e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—KRAS—melanoma	3.52e-06	1.58e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.52e-06	1.58e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ERCC2—melanoma	3.51e-06	1.58e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.51e-06	1.58e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—KRAS—melanoma	3.5e-06	1.58e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—HRAS—melanoma	3.48e-06	1.57e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—STAT3—melanoma	3.47e-06	1.56e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—AKT1—melanoma	3.47e-06	1.56e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NRAS—melanoma	3.46e-06	1.56e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CB—melanoma	3.45e-06	1.55e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK3—melanoma	3.44e-06	1.55e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—HRAS—melanoma	3.44e-06	1.55e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTGS2—melanoma	3.42e-06	1.54e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—AKT1—melanoma	3.42e-06	1.54e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—KRAS—melanoma	3.41e-06	1.53e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK3—melanoma	3.39e-06	1.52e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK3—melanoma	3.38e-06	1.52e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—KRAS—melanoma	3.36e-06	1.51e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—PIK3CA—melanoma	3.35e-06	1.51e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MYC—melanoma	3.35e-06	1.51e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IL6—melanoma	3.33e-06	1.5e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK3—melanoma	3.32e-06	1.49e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MYC—melanoma	3.29e-06	1.48e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IL6—melanoma	3.29e-06	1.48e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MYC—melanoma	3.29e-06	1.48e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK1—melanoma	3.28e-06	1.47e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EGFR—melanoma	3.27e-06	1.47e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—AKT1—melanoma	3.26e-06	1.47e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—VEGFA—melanoma	3.26e-06	1.46e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CB—melanoma	3.25e-06	1.46e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TP53—melanoma	3.24e-06	1.46e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—PIK3CA—melanoma	3.24e-06	1.46e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MYC—melanoma	3.23e-06	1.45e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—STAT3—melanoma	3.23e-06	1.45e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK1—melanoma	3.22e-06	1.45e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTGS2—melanoma	3.22e-06	1.45e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EGFR—melanoma	3.22e-06	1.45e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—PIK3CA—melanoma	3.22e-06	1.45e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NRAS—melanoma	3.22e-06	1.45e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK1—melanoma	3.22e-06	1.45e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EGFR—melanoma	3.21e-06	1.45e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK1—melanoma	3.16e-06	1.42e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EGFR—melanoma	3.15e-06	1.42e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—AKT1—melanoma	3.15e-06	1.42e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PIK3CA—melanoma	3.13e-06	1.41e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TP53—melanoma	3.13e-06	1.41e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TP53—melanoma	3.12e-06	1.4e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—HRAS—melanoma	3.1e-06	1.39e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—KRAS—melanoma	3.09e-06	1.39e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PIK3CA—melanoma	3.08e-06	1.39e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK3—melanoma	3.08e-06	1.39e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—AKT1—melanoma	3.07e-06	1.38e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—AKT1—melanoma	3.06e-06	1.38e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—KRAS—melanoma	3.04e-06	1.37e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PIK3CA—melanoma	3.04e-06	1.37e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—KRAS—melanoma	3.04e-06	1.37e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—AKT1—melanoma	3.03e-06	1.36e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TP53—melanoma	3.03e-06	1.36e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MYC—melanoma	3e-06	1.35e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—HRAS—melanoma	2.99e-06	1.35e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTEN—melanoma	2.98e-06	1.34e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TP53—melanoma	2.98e-06	1.34e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—KRAS—melanoma	2.98e-06	1.34e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—HRAS—melanoma	2.98e-06	1.34e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL6—melanoma	2.97e-06	1.34e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.93e-06	1.32e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EGFR—melanoma	2.93e-06	1.32e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—HRAS—melanoma	2.9e-06	1.3e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL6—melanoma	2.87e-06	1.29e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—HRAS—melanoma	2.85e-06	1.28e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL6—melanoma	2.85e-06	1.28e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PIK3CA—melanoma	2.84e-06	1.28e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTEN—melanoma	2.81e-06	1.26e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PIK3CA—melanoma	2.8e-06	1.26e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PIK3CA—melanoma	2.79e-06	1.25e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PIK3CA—melanoma	2.79e-06	1.25e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CG—melanoma	2.77e-06	1.25e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL6—melanoma	2.77e-06	1.25e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—KRAS—melanoma	2.77e-06	1.25e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TP53—melanoma	2.75e-06	1.24e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—AKT1—melanoma	2.74e-06	1.23e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.74e-06	1.23e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL6—melanoma	2.73e-06	1.23e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TP53—melanoma	2.71e-06	1.22e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TP53—melanoma	2.7e-06	1.21e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PPARG—melanoma	2.68e-06	1.2e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TP53—melanoma	2.65e-06	1.19e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—AKT1—melanoma	2.64e-06	1.19e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—AKT1—melanoma	2.63e-06	1.18e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—HRAS—melanoma	2.63e-06	1.18e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—HRAS—melanoma	2.59e-06	1.16e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—HRAS—melanoma	2.58e-06	1.16e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—AKT1—melanoma	2.56e-06	1.15e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.54e-06	1.14e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—HRAS—melanoma	2.53e-06	1.14e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—AKT1—melanoma	2.52e-06	1.13e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL6—melanoma	2.52e-06	1.13e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—AKT1—melanoma	2.49e-06	1.12e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL6—melanoma	2.48e-06	1.11e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL6—melanoma	2.47e-06	1.11e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TP53—melanoma	2.46e-06	1.11e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CD—melanoma	2.44e-06	1.1e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL6—melanoma	2.42e-06	1.09e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ALB—melanoma	2.41e-06	1.08e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—HRAS—melanoma	2.35e-06	1.06e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—AKT1—melanoma	2.32e-06	1.04e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—AKT1—melanoma	2.28e-06	1.03e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—AKT1—melanoma	2.28e-06	1.02e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—AKT1—melanoma	2.28e-06	1.02e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL6—melanoma	2.25e-06	1.01e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—AKT1—melanoma	2.24e-06	1.01e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CB—melanoma	2.13e-06	9.56e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS2—melanoma	2.11e-06	9.47e-06	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CA—melanoma	2.1e-06	9.46e-06	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—AKT1—melanoma	2.08e-06	9.34e-06	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CA—melanoma	1.98e-06	8.91e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTEN—melanoma	1.84e-06	8.26e-06	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—AKT1—melanoma	1.72e-06	7.73e-06	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—AKT1—melanoma	1.62e-06	7.28e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CA—melanoma	1.3e-06	5.83e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AKT1—melanoma	1.06e-06	4.76e-06	CbGpPWpGaD
